Alliance/A222301
Trial Overview
Official Title
HIGH-DOSE PROPHYLACTIC GABAPENTIN (HOPE) TO PREVENT OPIOID USE FOR ORAL MUCOSITIS PAIN DURING HEAD AND NECK CHEMORADIOTHERAPY: A PHASE III CLINICAL TRIAL
Study Purpose
To determine if an escalating dose of gabapentin given from the beginning of radiation and throughout treatment will lower the amount of pain experienced by patients such that they need less opioid medication.
Diagnosis
Squamous cell carcinoma of the head and neck region Stage I-IV with planned cisplatin-based chemoradiation therapy.Eligibility
No prior surgery/treatment for head and neck cancer. Able to swallow capsules. No planned surgical treatment or maintenance immunotherapy for this cancer. No prescribed medications for chronic pain or neuropathy.
Intervention
Prophylactic Gabapentin vs. Placebo
For more information, click the link below:
https://clinicaltrials.gov/study/NCT06992427?term=A222301&rank=1
Key Participation Requirements
Trial Location(s)
Gender
male and female
Age
19 and over
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
A222301